The authors foundthat, in that cohort, BRCA1 and BRCA2 mutations accounted for nearly 50% of allgermline variants, and the third most common mutation was of the P53 gene.According to the current ACR recommendations, in patients at increased risk forbreast cancer based on genetics (those with a BRCA1 or BRCA2 mutation),screening MRI should be performed annually starting at 25–30 years of age. The gene discussed is TP53; the disease is cancer.